SES
10.4.2018 18:02:11 CEST | Business Wire | Press release
Following major space and ground infrastructure investments and the expansion of its Latin America video neighbourhood, SES today announced the launch of its Ultra HD platform into the region to accelerate commercial 4K rollouts among leading cable, IPTV, and DTH providers across Latin America.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180410006195/en/
Many of Latin America’s leading Pay TV providers are already testing SES’s new Ultra HD solution, an all-in-one package of pre-configured Ultra HD content, reception equipment, and satellite distribution that will enable quick and easy Ultra HD deployments over the region. The new SES Latin America Ultra HD solution will open with four Ultra HD channels, including NASA TV UHD, produced by Harmonic, as well as the SES Ultra HD demo channel, an incubator for emerging 4K content producers. SES plans to add new channels and content produced in Brazil, Mexico, and other Latin American countries in the future.
Like SES’s North America Ultra HD solution, the end-to-end Latin America platform will be distributed over multiple SES satellites. SES-6 will provide dedicated delivery across 100% of the Brazilian market, offering programming flexibility for local content. SES’s NSS-806 satellite, home to SES’s leading Latin American Pay TV neighbourhood, will serve the rest of the region until it is replaced by the recently launched SES-14 satellite later this year. Once SES-14 initiates service, SES plans to significantly expand the Latin America channel lineup on its expanding video neighbourhood at 47.5 West. SES is the unmatched leader in global HD and Ultra HD distribution, and has experienced unprecedented 18% year-on-year growth in Latin America with over 300 HD and Ultra HD channels currently hosted on its satellites.
“SES is ushering in an exciting new era of advanced television services across the region with the launch of our new Latin America Ultra HD platform – the latest game-changing solution built on SES’s robust network of space and ground infrastructure. The SES network is enabling the efficient delivery of HD, Ultra HD, and OTT content to audiences throughout the region,” said Jurandir Pitsch, Vice President, Sales and Market Development for SES Video in Latin America and the Caribbean. “Latin America’s leading Pay TV providers are poised to offer Ultra HD content to their subscribers via the SES platform ahead of the 2018 World Cup, which is driving strong interest in 4K services across the region.”
The SES-backed antenna programme, which led to the installation of satellite antennas at Pay TV distribution hubs throughout Latin America, puts SES in a prime position to help cable, IPTV and DTH providers reach 100% of the region’s vast audiences with advanced HD and Ultra HD content.
Learn more about the SES UHD platform
Follow us on:
About SES
SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 16 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in two key business units: SES Video and SES Networks. The company provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions. SES’s portfolio includes ASTRA, O3b and MX1, a leading media service provider that offers a full suite of innovative digital video and media services. SES is listed on the Euronext Paris and Luxembourg Stock Exchange (ticker: SESG). Further information available at: www.ses.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20180410006195/en/
Contact:
SES
Markus Payer
Corporate Communications & PR
Tel.
+352 710 725 500
Markus.Payer@ses.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom